Groupe d'Etude en Oncologie du Quebec

Titre	A Phase Ib/II Open-label, Multi-center Dose Escalation Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
Protocole ID	KontRASt-01
ClinicalTrials.gov ID	NCT04699188
Type(s) de cancer	Tumeurs solides
Phase	Phase I-II
Type étude	Clinique
Médicament	JDQ443
Institution	CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL
Ville	Montréal
Investigateur(trice) principal(e)	Dr Mustapha Tehfé
Coordonnateur(trice)	Adeline Hamon 514-890-8000 poste 30737
Statut	Actif en recrutement
Critètes d'éligibilité	Adult patients with advanced (metastatic or unresectable) KRAS G12C mutant solid tumors Prior treatment with a KRAS G12C inhibitor may be allowed for dose escalations of combinations
Critètes d'exclusion	Tumors harboring driver mutations that have approved therapies or tumors with known activating KRAS, NRAS, HRAS, BRAF or PTPN11 (SHP2) mutations, with exception of KRAS G12C mutations Active brain metastases Clinically significant cardiac disease or risk factors at screening

Groupe d'étude en oncologie du Québec